Illumina (ILMN) : Eqis Capital Management reduced its stake in Illumina by 2.57% during the most recent quarter end. The investment management company now holds a total of 9,802 shares of Illumina which is valued at $1,824,838 after selling 259 shares in Illumina , the firm said in a disclosure report filed with the SEC on Oct 4, 2016.Illumina makes up approximately 0.11% of Eqis Capital Management’s portfolio.
Other Hedge Funds, Including , Norman Fields Gottscho Capital Management reduced its stake in ILMN by selling 389 shares or 4.84% in the most recent quarter. The Hedge Fund company now holds 7,644 shares of ILMN which is valued at $1,423,083. Illumina makes up approx 0.95% of Norman Fields Gottscho Capital Management’s portfolio.
Illumina closed down -1.01 points or -0.55% at $181.22 with 9,30,680 shares getting traded on Tuesday. Post opening the session at $182.38, the shares hit an intraday low of $180.03 and an intraday high of $186.61 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by CL King to ” Neutral” on Aug 22, 2016. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.